Open AccessSEL1L plays a major role in human malignant gliomas
Author(s) -
Mellai Marta,
Annovazzi Laura,
Boldorini Renzo,
Bertero Luca,
Cassoni Paola,
De Blasio Pasquale,
Biunno Ida,
Schiffer Davide
Publication year - 2020
Publication title -
the journal of pathology: clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.849
H-Index - 21
ISSN - 2056-4538
DOI - 10.1002/cjp2.134
Subject(s) - biology , cancer research , cell growth , sox2 , immunohistochemistry , pathology , gene , immunology , transcription factor , medicine , genetics
Suppressor of Lin‐12‐like ( C. elegans ) (SEL1L) participates in the endoplasmic reticulum‐associated protein degradation pathway, malignant transformation and stem cell biology. We explored the role of SEL1L in 110 adult gliomas, of different molecular subtype and grade, in relation to cell proliferation, stemness, glioma‐associated microglia/macrophages (GAMs), prognostic markers and clinical outcome. SEL1L protein expression was assessed by immunohistochemistry and Western blotting. Genetic and epigenetic alterations were detected by molecular genetics techniques. SEL1L was overexpressed in anaplastic gliomas (World Health Organization [WHO] grade III) and in glioblastoma (GB, WHO grade IV) with the highest labelling index (LI) in the latter. Immunoreactivity was significantly associated with histological grade ( p = 0.002) and cell proliferation index Ki‐67/MIB‐1 ( p = 0.0001). In GB, SEL1L co‐localised with stemness markers Nestin and Sox2. Endothelial cells and vascular pericytes of proliferative tumour blood vessels expressed SEL1L suggesting a role in tumour neo‐vasculature. GAMs consistently expressed SEL1L. SEL1L overexpression was significantly associated with TERT promoter mutations ( p = 0.0001), EGFR gene amplification ( p = 0.0013), LOH on 10q ( p = 0.0012) but was mutually exclusive with IDH1/2 mutations ( p = 0.0001). SEL1L immunoreactivity correlated with tumour progression and cell proliferation, conditioning poor patient survival and response to therapy. This study emphasises SEL1L as a potential biomarker for the most common subgroup of TERT mutant/ EGFR amplified/ IDH‐ WT GBs.